Get the Stockscreener App
3.85
0.78%
-0.04
Larimar Therapeutics Inc stock is traded at $3.85, with a volume of 672.12K.
It is down -0.78% in the last 24 hours and down -20.74% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.89
Open:
$3.86
24h Volume:
672.12K
Relative Volume:
0.26
Market Cap:
$329.95M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.5833
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
-11.06%
1M Performance:
-20.74%
6M Performance:
+29.96%
1Y Performance:
-50.13%
1-Day Range:
$3.76
$4.0596
1-Week Range:
$3.76
$4.495
52-Week Range:
$1.61
$9.50
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.855 | 332.95M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Why Larimar Therapeutics Inc. stock is favored by pension fundsWeekly Profit Report & Daily Volume Surge Trade Alerts - newser.com
Will Larimar Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - newser.com
What institutional flow reveals about Larimar Therapeutics Inc.July 2025 Catalysts & Smart Allocation Stock Reports - newser.com
What machine learning models say about Larimar Therapeutics Inc.Earnings Trend Report & Capital Efficient Trade Techniques - newser.com
How moving averages guide Larimar Therapeutics Inc. tradingTrade Risk Summary & Community Trade Idea Sharing - newser.com
Why Larimar Therapeutics Inc. (ZA71) stock stays undervaluedSwing Trade & Community Verified Trade Alerts - newser.com
How geopolitical risks impact Larimar Therapeutics Inc. (ZA71) stockMarket Growth Summary & AI Optimized Trade Strategies - newser.com
How Larimar Therapeutics Inc. (ZA71) stock behaves in tightening cycles2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Is Larimar Therapeutics Inc. (ZA71) stock positioned for digital growth era2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Detecting price anomalies in Larimar Therapeutics Inc. with AIWeekly Gains Summary & Fast Exit and Entry Trade Guides - newser.com
Will Larimar Therapeutics Inc. stock benefit from automationEarnings Beat & AI Enhanced Trading Alerts - newser.com
Price action breakdown for Larimar Therapeutics Inc.Weekly Gains Summary & Safe Capital Allocation Plans - newser.com
Custom watchlist performance reports with Larimar Therapeutics Inc.July 2025 Final Week & Low Drawdown Trading Strategies - newser.com
How Larimar Therapeutics Inc. stock trades during market volatilityPortfolio Return Report & High Yield Equity Trading Tips - newser.com
Larimar Therapeutics Inc. stock retracement – recovery analysisPortfolio Growth Summary & Technical Entry and Exit Alerts - newser.com
Will Larimar Therapeutics Inc. stock gain from lower inflationWeekly Trade Review & Step-by-Step Trade Execution Guides - newser.com
What makes Larimar Therapeutics Inc. stock attractive to growth fundsJuly 2025 Volume & Reliable Price Breakout Alerts - newser.com
Pattern recognition hints at Larimar Therapeutics Inc. upsidePortfolio Update Report & Weekly Hot Stock Watchlists - newser.com
Is Larimar Therapeutics Inc. (ZA71) stock worth buying before Fed actionMarket Performance Recap & AI Optimized Trading Strategy Guides - newser.com
Published on: 2025-11-01 00:49:57 - newser.com
Multi factor analysis applied to Larimar Therapeutics Inc.July 2025 Chart Watch & Safe Entry Point Identification - newser.com
What analysts say about Larimar Therapeutics Inc ZA71 stockDividend Aristocrats List & Superior Capital Growth - earlytimes.in
2025-10-31 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Larimar Therapeutics, Inc. (LRMR) And Encourages Shareholders to Reach Out | NDAQ:LRMR | Press Release - Stockhouse
Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia - MSN
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):